Ocular Therapeutix OCUL EBITDA margin

EBITDA margin at other companies

Regeneron PharmaceuticalsREGN

28.1%-2.5pp

EyePoint, Inc.EYPT

-11,272%-11,657pp

Bausch + LombBLCO

13.8%+4.3pp

HRO

HarrowHROW

8%+5.0pp

Tarsus Pharmaceuticals, Inc.TARS

-7.6%-3.3pp

PTH

Pelthos TherapeuticsPTHS

-145.4%—

FAQ

What is Ocular Therapeutix's EBITDA margin?

Ocular Therapeutix (OCUL) reported EBITDA margin of -566.5% in Q1 2026.

How has Ocular Therapeutix's EBITDA margin changed year-over-year?

Ocular Therapeutix's EBITDA margin decreased by 68.8% year-over-year, from -335.7% to -566.5%.

What is the long-term trend for Ocular Therapeutix's EBITDA margin?

Over 5 years (2020 to 2025), Ocular Therapeutix's EBITDA margin has grown at a 8.2% compound annual growth rate (CAGR), from -345.2% to -511.4%.

What does EBITDA margin mean?

EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.